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Abstract
We lack the understanding of why HIV-infected individuals in South Africa progress to AIDS. We hypothesised that in end-
stage disease there is a shifting dynamic between T cell imposed immunity and viral immune escape, which, through both
compensatory and reverting viral mutations, results in increased viral fitness, elevated plasma viral loads and disease
progression. We explored how T cell responses, viral adaptation and viral fitness inter-relate in South African cohorts
recruited from Bloemfontein, the Free State (n=278) and Durban, KwaZulu-Natal (n=775). Immune responses were
measured by c-interferon ELISPOT assays. HLA-associated viral polymorphisms were determined using phylogenetically
corrected techniques, and viral replication capacity (VRC) was measured by comparing the growth rate of gag-protease
recombinant viruses against recombinant NL4-3 viruses. We report that in advanced disease (CD4 counts ,100 cells/ml), T
cell responses narrow, with a relative decline in Gag-directed responses (p,0.0001). This is associated with preserved
selection pressure at specific viral amino acids (e.g., the T242N polymorphism within the HLA-B*57/5801 restricted TW10
epitope), but with reversion at other sites (e.g., the T186S polymorphism within the HLA-B*8101 restricted TL9 epitope),
most notably in Gag and suggestive of ‘‘immune relaxation’’. The median VRC from patients with CD4 counts ,100 cells/ml
was higher than from patients with CD4 counts $500 cells/ml (91.15% versus 85.19%, p=0.0004), potentially explaining the
rise in viral load associated with disease progression. Mutations at HIV Gag T186S and T242N reduced VRC, however, in
advanced disease only the T242N mutants demonstrated increasing VRC, and were associated with compensatory
mutations (p=0.013). These data provide novel insights into the mechanisms of HIV disease progression in South Africa.
Restoration of fitness correlates with loss of viral control in late disease, with evidence for both preserved and relaxed
selection pressure across the HIV genome. Interventions that maintain viral fitness costs could potentially slow progression.
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Introduction
With few exceptions, untreated individuals infected with
Human Immunodeficiency Virus Type 1 (HIV-1) develop
Acquired Immunodeficiency Syndrome (AIDS), associated with
opportunistic infections, malignancies and, eventually, death.
Some patients progress to AIDS quickly, whilst others maintain
undetectable plasma viral loads without therapy and do not
become unwell for many years. Deciphering the correlates of this
heterogeneous protection is important, as there are implications
for the design of vaccines and other interventions.
The pace of HIV disease progression is multifactorial - a
mixture of host and pathogen genetics combined with factors such
as the immune response and viral adaptation. In genome-wide
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Cloete  van  Vuuren,    John  Fraterassociation studies a limited number of SNPs and alleles correlate
with lower viral loads [1][2], and HLA Class I and the human
MHC associate reproducibly [3]. The role of the cell-mediated
immune system in HIV-associated disease has received much
scrutiny, especially the effect of different HLA Class I alleles. Well-
documented examples include the protection conferred by HLA
B*57 and B*27 [4][5] in Caucasian individuals and HLA B*5801
and B*8101 in patients from South Africa [6].
What determines this differential HLA Class I effect is unclear.
‘Beneficial’ HLA Class I alleles may be associated with T cell
clones with broader cross-reactivity to viral variants due to
reduced thymic selection [7], and thus broader and more
pervasive selection pressure. However, HIV is adept at adapting
to selection pressures invoked by both antiretroviral drugs (ARVs)
and the immune system in the forms of drug resistance [8][9] and
immune escape mutations [10][11], respectively. The latter are
widespread across the HIV-1 genome [12][13][14], and may
influence outcome in individual patients [15] and across different
populations [16].
Escape from an effective immune response is determined by the
strength of the imposed selection pressure and may explain why
the prevalence of HLA-associated polymorphisms is greater for
HLA Class I alleles associated with protection [17]. Although the
adapted virus maintains a fitness advantage in the presence of the
selection pressure conferred by cytotoxic T cells (CTL), there may
be a significant drop in replicative capacity compared to a wild-
type virus in a selection-free environment [18][19]. We, and
others, have previously hypothesised that immune escape may
therefore result in the maintenance of relatively lower viral loads
and clinical advantage [17] [20,21]. This is supported by high
reversion rates of escape mutations selected by ‘beneficial’ HLA
Class I alleles following transmission to HLA-mismatched
recipients [22][23].
These interactions between HLA Class I imposed selection,
viral escape and viral fitness are together likely to influence clinical
progression, however the mechanisms that lead to progression to
late disease and AIDS are poorly defined. We hypothesised that
the nature of these interactions can be understood better by
investigating patients with late-stage HIV infection to determine if,
or how, CD8+ve T cells are maintaining selection pressure, and
whether the virus shows different patterns of adaptation and fitness
costs compared to patients with earlier infection. There are limited
reports that, despite the loss of CD4+ve cells, CD8+ve T cells may
still be functional in AIDS, although with varied avidity, less
polyfunctionality and less differentiation [24], and targeting Env
rather than Gag [25]. We proposed that if CD8 T cell pressure is
‘relaxed’ due to HIV-induced immunodeficiency this might
facilitate reversion of costly escape mutations, leading to a
restoration of viral fitness and the subsequent rise in viraemia
seen in AIDS. Reversion of costly drug resistance mutations has
been associated with a rise in viral load and clinical progression
[26], and therefore a precedent exists to potentially explain the rise
in viral load associated with the onset of AIDS. Alternatively, CTL
pressure may be maintained, but the virus might develop
secondary compensatory mutations, which restore the replicative
cost of the initial escape mutation. Compensatory mutations have
been reported in chronic infection [27,28], but whether they
explain the AIDS-associated rise in viraemia is not known.
In this study we question whether progression to AIDS is
associated with an increase in viral fitness, and whether this is
related to changes in T cell imposed selection pressure. We start by
comparing T cell ELISPOT responses in patients across different
CD4 count strata, and then examine how the variation in these
responses correlates with different patterns of selection across the
HIV genome in patients with very low CD4 cell counts compared
with less progressed infections. Finally, we measure the viral fitness
of these variants to correlate the replicative cost of adaptation with
outcome. We investigated 1053 untreated HIV-1 infected South
African individuals from Bloemfontein and Durban, and found
that viral fitness was greater in patients with advanced disease with
examples of both viral compensatory mutations and of reduction
in escape mutations, the latter possibly due to ‘immune relaxation’.
Despite the complex interplay between host and pathogen, these
data support a key role for the restoration of viral fitness in
association with AIDS progression and help to explain the rise in
viraemia in terminal stages.
Methods
Ethics Statement
Full ethical approval was gained for the study of both cohorts.
Written informed consent was provided by all study participants.
The study ethics for the Bloemfontein cohort was approved by the
University of the Free State (ETOVS 10/04 and ETOVS 206/05)
and for the Durban cohort by the University of KwaZulu-Natal
Review Board.
Study subjects
Participants from two South African cohorts were studied (total
n=1053) - the ‘Bloemfontein’ cohort from the Free State (n=278)
and the ‘Durban’ cohort from KwaZulu-Natal (n=775). Both are
established cohorts, described elsewhere ([29] [6]). In summary,
each of the cohorts was comprised of antiretroviral naı ¨ve and
chronically HIV-1 subtype C-infected adults from neighbouring
provinces in the central east region of South Africa. Of these, 916
patients with data on CD4 cell count, HLA class I type and either
HIV gag, pol or nef sequences were included in the analysis of HLA-
linked polymorphisms, and comprised the ‘total’ cohort. Subse-
quent analyses involved stratification of the patients according to
HLA type, plasma viral load and CD4 T cell count. In the CD4 T
cell count stratification, patients were assigned to either ‘‘High
CD4’’ (CD4 T cell counts .500 cells/ml, n=299), or ‘‘Low CD4’’
(CD4 T cell counts ,100 cells/ml, n=196).
HLA typing
Participants’ HLA Class I type was determined to the oligo-
allelic level using Dynal RELITM Reverse Sequence-Specific
Oligonucleotide kits for the HLA-A, -B and –C loci (Dynal
Biotech). To obtain four-digit typing, Dynal Biotech Sequence-
Specific priming kits were used, in conjunction with the Sequence-
Specific Oligonucleotide type.
T Cell ELISPOT assays
Peptides, 18 amino acids in length (n=410), overlapping by 10
amino acids, and spanning the entire expressed HIV genome,
were synthesized based on the consensus of available C-clade
sequences in 2001. These peptides were used in a ‘mega-matrix’ of
11–12 peptides per pool to test patient samples for HIV-specific T
cell responses by interferon-gamma ELISPOT assay, as previously
described [30]. Confirmation of recognised individual 18-mer
peptides within a peptide pool was carried out in separate
ELISPOT assays.
Sequencing of HIV gag, pol and nef
HIV gag, pol and nef were sequenced using previously described
methods and primers [17]. In brief, viral RNA was extracted from
plasma, reverse transcribed to cDNA and amplified using a nested
polymerase chain reaction (PCR) protocol. Population sequencing
Viral Fitness in Advanced AIDS
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sequencing kits (Applied Biosystems), according to manufacturer’s
instructions. Sequences were aligned manually using X11 and Se-
Al software.
Identification of HLA class I linked polymorphisms
Amino acid polymorphisms that associated with host HLA class
I alleles, were identified using previously described methods
utilising ‘phylogenetic dependency networks’ [31]. Briefly, the
analysis combines phylogenetic correction with a statistical model
of evolution to evaluate associations between host HLA class I
alleles and viral amino acid site-specific polymorphisms. The
analysis adjusts for confounding factors including founder effects,
linkage disequilibrium of host HLA types, co-variation in HIV
codons and corrections for multiple statistical tests. The signifi-
cance of an association is expressed as a ‘q value’, which estimates
the false discovery rate for each p-value. In this study an
association is considered significant for q,0.2. ‘Escape’ describes
increased polymorphisms observed at a particular amino acid site
in the presence of a specific HLA class I allele. ‘Reversion’
describes decreased polymorphisms observed at a particular amino
acid site in the absence of a specific HLA class I allele. The
strength of associations between HLA class I alleles and viral
polymorphisms in the ‘‘total’’ cohort, ‘‘high CD4’’ group or ‘‘low
CD4’’ group was derived using a logistic regression model that
corrected for phylogeny, and is reported as a log2-adjusted odds
ratio.
Identified polymorphisms were mapped to known cytotoxic T
cell epitopes. Epitope maps were defined from experimental data
from the Durban cohort [6], and from those listed in the A-list of
Los Alamos Database (http://www.hiv.lanl.gov/content/immunology/
pdf/2008/optimal_ctl_article.pdf). The epitope flanking region was
also included in the analysis, defined according to the five amino
acids neighbouring to the defined epitope in both C and N
terminal directions.
Generation of chimeric NL4-3 viruses
Chimeric viruses were constructed by recombining a gag-protease-
deleted pNL4-3 HIV plasmid (pNL4-3Dgag-protease) with autolo-
gous gag-protease amplified from virus extracted from patient
plasma, as described elsewhere [19,32,33,34].
In brief,to amplify the autologous HIV gag-protease viral RNA was
extracted from plasma, reverse transcribed and amplified using
specific primers in the first round of nested PCR using the
Superscript III One-step RT-PCR kit with high fidelity Platinum
Taq polymerase (Invitrogen) (forward primer: 59 AAATCTCTAG-
CAGTGGCGCCCGAACAG 39, HXB2 nucleotides 623 to 649;
reverse primer: 59 TTTAACCCTGCTGGGTGTGGTATYCCT
39, HXB2 nucleotides 2851 to 2825). The second round of the
nested PCR was conducted using a 100-mer primer pair (forward
primer: 59 GACTCGGCTTGCTGAAGCGCGCACGGCAA-
GAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAA-
TTTTGACTAGCGGAGGCTAGAAGGAGAGAGATGGG 39,
HXB2 nucleotides 695 to 794; reverse primer: 59 GGCCC-
AATTTTTGAAATTTTTCCTTCCTTTTCCATTTCTGTAC-
AAATTTCTACTAATGCTTTTATTTTTTCTTCTGTCAAT-
GGCCATTGTTTAACTTTTG 39, HXB2 nucleotides 2704 to
2605) that completely matched the pNL4-3 sequences using
Platinum Taq polymerase (Invitrogen).
The pNL4-3 HIV plasmid had been mutated to contain unique
restriction enzyme (BstEII) sites at the 59 end of the gag gene and 45
nucleotides downstream from the 39 end of the protease gene, as
described elsewhere [19]. The BstEII enzyme digest results in
deletion of HIV gag-protease and self ligation of the remaining
plasmid (pNL4-3Dgag-protease). For transfection, the pNL4-3Dgag-
protease was linearised by BstEII digestion for two hours at 60uC
(10 U/ml of enzyme per 1000 mg/mL of plasmid). For each
sample, 10 mg of the linearised pNL4-3Dgag-protease was co-
transfected with 5 mg of patient-derived gag-protease PCR product
in 3.9610
6 tat-driven GFP reporter T cells (GXR cells of CEM
origin). After transfection by electroporation (250 V, 950 mF, for
30–40 msec), 10 ml polybrene (4 mg/ml) and 1610
6 GXR cells
were added and incubated at 37uC. Positive control samples were
generated using co-transfection of pNL4-3Dgag-protease with gag-
protease amplified from pNL4-3, pHXB2 (subtype B), and pMJ4
(subtype C). After five days, GFP expression was measured every
1,2 days using a FACSCalibur flow cytometer (FACSCalibur;
BD Biosciences, San Jose, CA). Supernatant was harvested when
.15% of cells were positive for GFP, and stored at 280uC.
Measurement of viral replication capacity (VRC)
Viral titration was performed in 1610
6 GXR cells to determine
the multiplicity of infection (MOI). The VRC was assayed by
adding recombinant virus supernatant to 1610
6 GXR cells at an
MOI of 0.003. The VRC was measured, at least in duplicate,
using gating strategies as previously described [19]. The growth of
virus was calculated from the slope derived from the natural log of
the percentage of GFP positive cells between days 2 and day 7, as
appropriate for an exponential growth curve. The final VRC of
each variant is expressed as percentage growth rate of the variants
compared to that of recombinant NL4-3 strains. In addition, for
each VRC assay, viral supernatants were collected on day 7 for
viral RNA extraction and sequencing to confirm the population
sequences VRC measured.
Statistics
Student t-tests (two tailed) and Mann-Whitney tests (two tailed)
were used to compare various clinical parameters and VRC
measurements. The statistical analyses were carried out using
Prism4 for Macintosh (GraphPad Software, version 4.0c).
Associations between HLA Class I alleles and viral polymorphisms
were determined using phylogenetically-corrected algorithms, as
described above.
Results
Structure of cohorts
Patients were recruited from the Bloemfontein and Durban
cohorts [29] [6]. The Bloemfontein cohort comprises 884 drug-
naı ¨ve patients at all stages of HIV infection recruited through the
South African government ARV program. Plasma samples were
studied from 278 out of the 884 participants: 96 out of 110 patients
in the high (CD4 count.500 cells/ml), 18 out of 308 in an
intermediate (CD4 count=201–400 cells/ml), and 164 of 183 in
the low (CD4 count,100 cells/ml) strata. The samples were used
for the HLA-association study and to make recombinant viral
strains for the analysis of fitness. To increase the power of the
HLA-association analysis we incorporated HIV viral sequences
from the neighbouring Durban cohort, which comprised 775
adults, naive to antiretroviral therapy. Of these, 219 were
asymptomatic women identified through antenatal clinics. The
remaining 556 subjects were recruited from out-patient clinics. For
all 775 patients host HLA class I alleles were genotyped.
ELISPOT assays were carried out using overlapping peptides
designed from the subtype C majority consensus. For 656 of these
patients, sequences of either viral gag, pol and nef genes were
available.
Viral Fitness in Advanced AIDS
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disease
In order to measure the T cell-imposed selection pressure acting
on HIV at different stages of the infection, ELISPOT assays using
overlapping peptides (OLPs) covering the entire HIV genome
were analysed from 775 patients. Results were stratified according
to CD4 cell count and are presented according to the number of
OLPs seen per patient for each gene (Figure 1a), and the
percentage contribution of each protein to all responses in each
strata (Figure 1b). The figure shows that over the course of
infection, there is a general narrowing of the absolute breadth of
responses (Figure 1a). However, the relative contribution of Gag to
the total responses decreased (p,0.0001, r
2=0.055) in contrast to
the proportion of responses to other proteins such as Env
(p,0.0001, r
2=0.024) and Vif (p=0.003, r
2=0.011), which was
greater in patients with lower CD4 cell counts. We hypothesized
that the reduction in breadth of CD8+ve T cell responses might
result in, and therefore correlate with, a decline in selection
pressure, particularly in Gag in light of the relative shift away from
Gag targeting. As a result, this ‘immune relaxation’ might allow
the reversion of costly viral escape mutations back to a fitter wild
type state. Accordingly, we next analysed HLA Class I-associated
polymorphisms in the HIV-1 gag, pol and nef genes to identify any
difference in the strength of selection pressure in patients with high
and low CD4 cell counts.
Identification of HLA class I linked polymorphisms in
HIV-1 gag, pol and nef
To identify evidence of differential HLA Class I imposed
selection pressure in patients with high and low CD4 cell counts,
we carried out a study to identify HLA Class I associations with
particular amino acid polymorphisms in this cohort. We
accounted for potential confounding effects such as phylogeny,
founder effect and multiple comparisons by using phylogenetic
dependency networks [31] - an approach which reports associa-
tions between specific viral polymorphisms and HLA Class I alleles
according to p value, q value (a measure of false positive error) and
a phylogenetically-adjusted odds ratio.
Initially, we analysed 916 HIV-1 gag, pol and nef sequences from
the combined Durban and Bloemfontein cohorts and then we
carried out sub-group analyses on patients with either ‘high’ (.500
cells/ml, n=299) or ‘low’ (,100 cells/ml, n=196) CD4 cell counts.
We then selected those HIV amino acid polymorphisms
significantly associated with an HLA Class I allele in either, or
both of, the ‘high’ or ‘low’ CD4 count group of patients for further
analysis. The results for gag, pol and nef are presented in Tables 1, 2
and 3, respectively. The tables detail each viral polymorphism and
its associated HLA Class I allele, whether the association lies in, or
within, the flanking region of a known restricted epitope and
whether this association is expected to revert in HLA-mismatched
hosts [35]. The q values for the statistically significant associations
for the whole cohort, the ‘high’ CD4 count subgroup (.500 cells/
ml) and ‘low’ CD4 count subgroup (,100 cells/ml) are shown,
followed by the log2-adjusted odds ratios for the ‘high’ and ‘low’
groups. In the final column, the p value is reported, when there is a
significant difference between the two odds ratios.
We identified 40, 91 and 20 associations, respectively, between
an HLA Class I allele and a viral polymorphism in the HIV-1 gag,
pol and nef genes, in either, or both of, the ‘high’ or ‘low’ CD4
count subgroups. Of these, 16, 28 and 7 associations in HIV-1 gag,
pol and nef, respectively, had significantly different log2-adjusted
odds ratios in the two subgroups. These 51 associations are shown
in Figure 2, according to HIV-1 gene. In gag, pol and nef,
respectively, there were 5/16 (31%), 24/28 (86%) and 7/7 (100%)
associations that were more prevalent in the ‘low CD4’ group.
These data show that, where we could detect a difference,
associations were more prevalent at lower CD4 counts in pol and
nef, suggestive of continued selection pressure, but that certain
associations – particularly in HIV-1 gag – were weaker. Why might
HLA associations become weaker as disease progresses? One
possible explanation is that as CTL pressure weakens due to
immune exhaustion and loss of breadth, escape mutations with
replicative fitness costs are no longer required by the virus. These
therefore revert back to wild-type, resulting in a reduction in the
observed log2-adjusted odds ratio. Thus, low-cost mutations
accumulate over the course of infection, leading to higher
prevalence in Nef and Pol, whereas high-cost mutations begin
reverting, leading to a lower prevalence in Gag.
If changes in selection pressure were resulting in an increase or
decrease in the prevalence of wild type virus during late-stage
disease, we would expect to find changes in viral replicative
capacity in patients with low CD4 cell counts. We therefore
undertook assays of viral fitness. As the HIV gag gene was
associated with the most potential examples of immune relaxation
we implemented a fitness assay targeting the gag gene and focussed
on three beneficial HLA Class I alleles (HLA B*57, HLA B*5801,
and HLA B*8101) and one allele associated with more rapid
progression, HLA B*5802. In particular, we highlighted two
associations: the T186S mutation in the TPQDLNTML (TL9)
epitope, restricted by B*8101, with an observed decrease in log2-
adjusted odds ratio from 18.38 to 7.25 in patients with high and
low CD4 cell counts, respectively, (consistent with immune
relaxation, p=0.0397, likelihood ratio test), and the B*57/
B*5801 restricted epitope TSTLQEQIAW (TW10), with log2-
adjusted odds ratios of 25.4 and 23.2 for high and low CD4 cell
count stratification analysis (p=0.12, likelihood ratio test, showing
no significant evidence of immune relaxation). We focussed on
these two associations as published data suggest that they are both
associated with significant viral fitness costs [32] [18,27] and yet in
this dataset they behave very differently in terms of changes in
log2-adjusted odds ratios.
Increased viral replication capacity (VRC) of chimeric HIV-1
NL4-3 at low CD4 counts and high plasma viral loads
To investigate further possible reasons for declining selection
pressure within Gag epitopes with progression to AIDS, we
considered the hypothesis that loss of CD8+ T-cell responses as
CD4 count declines results in reversion of escape mutants, with
resulting increase in viral replicative capacity. To investigate the
impact of the gag-protease mutations selected by different HLA class
I alleles at different clinical stages, we constructed 148 chimeric
HIV-1 NL4-3 viruses containing autologous gag-protease from
patients of the Bloemfontein cohort. Patients with specific HLA
class I alleles previously associated with control of HIV in this
population (HLA-B*57/5801/8101) or lack of control (B*5802)
[6] were selected for chimeric virus construction and stratified by
CD4 cell count. 88 viruses were constructed from patients with low
CD4 cell counts (,100 cells/ml), comprising HLA-B*57 (n=2),
HLA-B*5801 (n=15), HLA-B*5802 (n=54) and HLA-B*8101
(n=10) plus 14 ‘neutral/other’ (i.e. neither protective or
disadvantageous) HLA Class I alleles. From patients with high
CD4 cell counts (.500 cells/ml), 42 viruses were made: HLA-B*57
(n=7), HLA-B*5801 (n=8), HLA-B*5802 (n=15), HLA-B*8101
(n=10) plus 10 ‘neutral/other’ HLA Class I alleles. Sixteen
patients co-expressed two of these HLA class I alleles. A further 18
viruses were made from patients randomly selected from
intermediate CD4 T cell counts. The VRC of the chimeric virus
Viral Fitness in Advanced AIDS
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3Dgag-protease plasmid recombined with the wild type HIV-1 NL4-
3 gag-protease insert.
Initially we determined whether CD4 cell count alone was
associated with VRC. Figure 3a shows that the VRC of the
chimeric viruses from patients from different CD4 T cell count
strata was significantly different (Figure 3a). The VRC from viral
isolates from patients with the lowest CD4 T cell counts (,100
cells/ml, median 91.15%; IQR: 86.1–98.0%) was significantly
higher than from patients with high CD4 T cell counts (.500
cells/ml, median 85.19%; IQR: 79.8%–91.8%), p=0.0004
(Mann-Whitney test), showing that progression to AIDS is
associated with an increase in viral fitness.
There was also a weak but statistically significant positive
correlation between VRC and log10 plasma viral load (Figure 3b,
p=0.0003, r
2=0.088, n=142). The slope of the best-fit values
(0.02960.0079) indicated that a 34.4% increase in VRC
accounted for an increase of one log10 in plasma viral load.
VRC of chimeric gag-protease NL4-3 viruses varies
according to HLA class I
As higher VRCs were associated with higher plasma VL and
lower CD4 cell count, we examined how this effect varied
according to HLA Class I (Figure 4a). The VRC of chimeric
viruses derived from patients with the protective alleles HLA B*57
(median=83%, IQR: 76–89%; n=9) and HLA B*8101 (medi-
an=84%, IQR: 78–92%; n=20) was significantly lower than
from patients with ‘neutral/other’ HLA class I alleles (medi-
an=91%, IQR: 81–92%; n=26); (p=0.007 and p=0.005,
respectively), or from patients with HLA B*5802, associated with
more rapid clinical progression (median=91%, IQR: 85–98%,
n=68) (p=0.010 and p=0.008, respectively, Mann-Whitney
test).
To determine whether the association between HLA Class I and
viral fitness was additionally impacted by disease stage we stratified
the VRCs according to high and low CD4 cell counts (Figure 4b).
This sub-group analysis shows that the mean VRC values are
higher for each HLA Class I allele in the low CD4 count group
suggestive of an increase in viral fitness in advanced disease,
although in most cases these values are not statistically significant.
This is likely to be an effect of being underpowered, as patient
numbers become smaller with each sub-categorisation. Interest-
ingly, there is a significant difference in the VRCs of viruses in the
non-protective ‘neutral/other’ HLA Class I alleles (p=0.0092,
Mann-Whitney test), showing that although there is an HLA-
specific effect on viral fitness, there is an additional association
with CD4 cell count, independent of the more beneficial HLA
Class I alleles.
The impact of specific mutations on VRC in the context
of HLA-B*8101 and HLA-B*B57/B*58
These analyses have shown that viral fitness is greater in viruses
from patients with advanced disease, and that certain protective
HLA Class I alleles (such as B*57, B*8101 and B*5801) are
associated with greater fitness costs. The HLA-association analysis
presented above (Tables 1,2 and 3) revealed that in patients with
low CD4 counts HLA B*57/*5801 was associated with persistence
of T242N in the TW10 epitope, whereas HLA B*8101 was
associated with a potential loss of selection pressure reflected by
the decreased prevalence of T186S mutants in the TL9 epitope.
We therefore focused further on these well-characterised escape
mutants to investigate how they impacted viral fitness at different
stages of disease progression.
For HLA-B*8101, we excluded from the analysis any viruses
with key mutations restricted by other HLA Class I alleles (that is,
T242N and A163G) which were known to impact fitness. Viruses
from patients with HLA B*8101 were significantly less fit than
viruses from patients in the rest of the cohort (p=0.0059, Mann-
Whitney test; Figure 5a) and mutations in the B*8101-restricted
Gag TL9 epitope were associated with lower VRCs (p=0.024)
both in the whole cohort and in patients with HLA B*8101
(p=0.025). The main single mutation conferring loss of replicative
fitness was the T186S immune escape mutation (p,0.0001).
Neither the Q182S or T190X mutations had an impact on VRC
in this cohort (data not shown). Although patient numbers were
small, there was no significant difference between the VRCs of
viruses with the T186S mutation according to high and low CD4
count stratification. These data show that although B*8101
imposes a fitness cost on the virus through selection of T186S,
we found no evidence that, when this mutation persists, the fitness
cost is restored at low CD4 cell counts.
We compared the fitness costs associated with HLA B*8101
with those associated with B*57 and B*5801, as the HLA-
association analysis suggested that for these latter alleles escape
mutations persisted in advanced disease. We pooled the data for
patients with HLA B*57 and B*5801 as these alleles have highly
related binding motifs, and both present the Gag TW10 epitope
and select the T242N escape mutation [36]. As for HLA B*8101,
viruses from patients with HLA-B*57 or HLA-B*5801 were
significantly less fit than those from the rest of the cohort
(p=0.0299, Mann-Whitney test; Figure 5b), supporting the
association between protective HLA Class I alleles and viral
replicative cost (Figure 4a). In the whole cohort there was no
significant effect of all mutations in the TW10 epitope on VRC.
For patients with HLA B*57 or B*5801, there was a non-
significant trend for all mutations within the TW10 epitope to
impair fitness, although the power of this analysis was limited as
only one of the 22 patients had not selected a mutant epitope.
However, the fitness cost of the T242N mutation was confirmed
when the whole cohort was analysed, when it was associated with
a significant drop in VRC (p=0.0285). This result was
independent of the effect of mutations in other B*57/B*5801
associated epitopes such as Gag KF11 or Gag IW9 (p=0.024;
data not shown), showing that the fitness cost was associated with
T242N, rather than reflecting being positive for HLA B*57/
B*5801.
In the HLA-association analysis we had found that T242N was
maintained in late disease, even though these data, as well as
previous reports, suggest that this mutation is associated with a
fitness cost. We explored this apparent discrepancy by stratifying
the fitness analysis of T242N according to CD4 count (Figure 5b),
and found that in patients with advanced disease (CD4 counts
,100 cells/ml), viral fitness had been restored even though the
T242N persisted (p=0.0028).
Figure 1. Gamma interferon ELISPOT responses in patients with CD4 counts above and below 100 cells/ml. Recognition of overlapping
peptides covering the full HIV genome is shown in patients with CD4 cell counts above and below 100 cells/ml. ELISPOT responses are displayed as
(a.) the absolute breadth of responses, reflecting the mean number of overlapping peptides recognised by each patient for each HIV protein and, (b.)
the relative breadth, reflecting the proportion of ELISPOT responses targeted against different HIV proteins in patients within different CD4 count
strata.
doi:10.1371/journal.pone.0019018.g001
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PLoS ONE | www.plosone.org 13 April 2011 | Volume 6 | Issue 4 | e19018Figure 2. Changes in associations between HLA Class I alleles and HIV amino acid polymorphisms for patients with CD4 cell counts
,100 cells/ml compared with patients with CD4 cell counts .500 cells/ml. The change in the strength of associations between HLA Class I
alleles and specific HIV amino acid polymorphisms in patients with high and low CD4 cell counts is shown for HIV-1 (a.) Gag, (b.) Pol and (c.) Nef.
Change in strength of the association is reported on the Y-axis as a log(2)-adjusted value. Associations are recorded on the X-axis according to the
restricting HLA Class I allele and the specific viral polymorphism – e.g. B45-H28R in Gag means that in the presence of HLA B*45, Gag amino acid 28
mutates from a Histidine (H) to an Arginine (R). In this case there is at least a 40-fold change in the log(2)-adjusted odds ratio for this association in
patients with CD4 counts ,100 cells/ml compared with less progressed patients with CD4 cell counts .500 cells/ml. (All fold changes are capped at a
value of 40).
doi:10.1371/journal.pone.0019018.g002
Figure 3. Viral replication capacity (VRC) according to CD4 cell count and plasma viral load. The viral replicative capacity (VRC) of
chimeric NL4-3 viruses recombined with patient autologous gag-protease genes is compared with a laboratory recombinant HIV-1 NL4-3 strain. In
(a.), The VRC of isolates from the Bloemfontein cohort is presented stratified by CD4 T cell count. The p-values are calculated using the Mann-Whitney
test. In (b.), plasma viral load (log10 copies/ml) is correlated against the VRC from samples from the Bloemfontein cohort. In both panels VRC is
presented as a percentage relative to the fitness of the control NL4-3 virus.
doi:10.1371/journal.pone.0019018.g003
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PLoS ONE | www.plosone.org 15 April 2011 | Volume 6 | Issue 4 | e19018Compensatory mutations accrue in advanced HIV
infection in patients with HLA B*57 and B*5801
As the T242N mutation has been previously linked with
compensatory mutations we analysed our cohort to see if these
accrued in late stage disease to explain the rise in viral fitness
despite the maintenance of T242N. For the T242N mutation in
TW10, compensatory mutations have previously been published
(H219Q, I223V and M228) [27], and so we examined the
frequency of these mutations in the different CD4 T cell count
strata (Figure 6). We found a cumulative increase in the number of
compensatory mutations in patients with T242N in individuals
with lower CD4 cell counts, consistent with the increase in fitness
in the previous analyses (P=0.013).
Together these data suggest that advanced HIV disease is
associated with an increase in viral fitness, which may contribute
to the rise in plasma viral load frequently seen in AIDS. However,
this increase in fitness is multifactorial and we report two processes
specific to different HLA Class I alleles – reversion due to immune
relaxation and compensatory mutations – to potentially explain
these findings.
Discussion
In this study, we have explored the hypothesis that progression
to AIDS is associated with a rise in viral replicative capacity, and
the mechanisms associated with this. We proposed that a rise in
viral fitness in AIDS could be due either to a relaxation of CTL-
imposed selection pressure resulting in the reversion of costly
mutations or, alternatively, if immune pressure is maintained,
compensatory mutations might restore the fitness costs of
persisting escape mutations.
We initially tested the hypothesis by looking for evidence of
changes in T cell-imposed selection pressure measured by gamma
interferon ELISPOT assays. We found that the breadth of the
response narrowed as the CD4 count declined and that,
specifically, the contribution of Gag responses to the overall
response decreased. It has previously been reported that acute
HIV infection is associated with narrow, high affinity T cell
responses which broaden as patients progress into chronic
infection [37]. Here, we see the reverse of this process with a
return to a much narrower range of T cell responses. It would also
be interesting to measure whether there was a loss of high affinity
T cells in the advanced stage patients in this cohort as this might
be compatible with a weakening in selection pressure.
Although we identified a narrowing of the T cell responses in
AIDS, the ELISPOT data alone are not sufficient to infer changes
in selection pressure. We therefore looked for evidence of
differential selection in patients with high and low CD4 cell
counts using a statistical HLA Class I association study. By
combining sequence and HLA data from the Bloemfontein cohort
and the Durban cohort, we were able to define two groups of
patients with CD4 counts less than 100 cells/ml (n=196) and
greater than 500 cells/ml (n=299). These CD4 count strata were
defined to represent extremes of HIV-related disease without
reducing the power of the analysis. The WHO have defined that
antiretroviral therapy should be commenced at a CD4 count of
350 cells/ml. Below 200 cells/ml, opportunistic infections become
more common. A count of 100 cells/ml or below, therefore,
represents advanced HIV disease and progression to AIDS. Above
500 CD4 cells/ml it would be highly unusual for there to be
opportunistic infections and the most recent NIH guidelines do not
recommend treating above this level [38].
To identify mutations in the HIV genome associated with
individual HLA Class I alleles we used an established technique
using phylogenetic dependency networks [31], which has been
widely implemented in the HIV literature [12,14,35,39]. In this
approach, the risk of error due to viral founder effects and
misidentification of co-variant sites is corrected for by integrating
the phylogeny of the sequences into the analysis. Identified
associations are hypothesised to be the result of cytotoxic T cell
imposed selection pressure and in other analyses such associations
have been proven experimentally. Although there have been a
number of HLA-association studies reported, none have stratified
patients according to disease progression and compared the
strength of selection in different strata according to log2-adjusted
odds ratios.
In our cohorts we identified 151 HLA-associated mutations in
HIV-1 gag, pol or nef that were significant in patients with either
high or low CD4 cell counts. By comparing log2 adjusted odds
ratios in the CD4 strata, we found that there was evidence for
both immune relaxation and intensification in patients with low
CD4 counts compared with high CD4 counts. This suggests that
for some HLA Class I–restricted responses the selection pressure
imposed by CTL is maintained at very low CD4 cell counts but
that for others there may be reversion of escape mutations
associated with a reduction in selection pressure. Interestingly,
the majority of events compatible with immune relaxation were
in HIV Gag, which was also the protein for which there was a
relative narrowing of T cell ELISPOT responses in AIDS
patients.
Two key sites potentially reflecting immune ‘persistence’ and
‘relaxation’ were the HLA B*57/B*5801 associated T242N
mutation and the B*8101 associated T186S mutation, respective-
ly. For the former, the association analysis provided evidence for
on-going mutation associated with compensatory mutations,
whereas for the latter there was evidence for reversion. A
limitation of this study is that it is cross-sectional rather than
longitudinal, potentially biasing our data interpretation. An
alternative explanation for immune relaxation is that the patients
who progress are the ones who do not make an immune response
and so do not select mutants, therefore enriching patients with low
CD4 counts with wild-type viruses. This would be compatible with
the finding that targeting certain key epitopes may be associated
with different speeds of clinical progression [40], but does not
explain the eventual outcome of those patients enriched for
immune escape mutations with high CD4 cell counts. To
determine which occurs would require a prospective longitudinal
study of untreated progression to AIDS. In our cohort, analyses of
HLA B*8101 positive individuals with data on ELISPOT
responses and viral sequence, show that for patients with CD4
counts between 200–500 cells/ml, 50% (3/6) who did not
recognise TL9 carried the T186S mutant. In contrast, for patients
with CD4 counts ,100 cells/ml there were no ELISPOT negative
patients with T186S (0/2), suggesting that these had reverted
Figure 4. Viral replication capacity according to HLA Class I and CD4 cell count. (a) Viral replication capacity (VRC) of chimeric NL4-3 viruses
containing patient autologous gag-protease stratified by HLA Class I. The VRC is expressed as percentage growth rate compared to control strains.
The p-value is calculated using Mann-Whitney test. Panel (b.) shows further stratification according to CD4 cell count. The y-axis depicts VRC,
expressed as percentage growth and the x-axis depicts HLA class I, with each HLA class I category divided further into ‘‘low’’ CD4 T cell count strata
(,100 cells/mm3) and ‘‘high’’ CD4 T cell count (.500 cells/mm3). The p-value is calculated using Mann-Whitney test.
doi:10.1371/journal.pone.0019018.g004
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PLoS ONE | www.plosone.org 16 April 2011 | Volume 6 | Issue 4 | e19018Figure 5. Viral replication capacity (VRC) in viruses with mutants in (a) Gag TL9 and (b) Gag TW10 according to HLA Class I and CD4
cell count. In panel (a), the y-axis depicts viral replication fitness (VRC) of chimeric NL4-3 viruses containing patient autologous gag-protease,
expressed as percentage growth rate compared to a control recombinant NL4-3 strain. The x-axis depicts the stratification of patients according to (i)
HLA-B*8101, (ii) polymorphic status within the gag TL9 epitope in all patients, (iii) polymorphic status of gag TL9 in patients with HLA B*8101, (iv)
presence of T186S in gag in Gag TL9, and (v) T186S further stratified according to the CD4 T cell count (,100 cells/mlo r.500 cells/ml). The p-value is
calculated using Mann-Whitney test. In (b), patients are stratified according to (i) HLA-B*57 or B*5801 alleles, (ii) polymorphic status within the gag
TW10 epitope, (iii) polymorphic status of TW10 in patients with HLA-B*57 or B*5801 alleles, (iv) polymorphic status of amino acid position 242 (within
TW10 epitope – T242N) in all patients and (v) by T242N in patients with HLA-B*57 or B*5801 according to CD4 count. The viral isolates possessing
other known costly escape mutations (A163G and T186S) are excluded from this analysis. The p-value is calculated using Mann Whitney test.
doi:10.1371/journal.pone.0019018.g005
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PLoS ONE | www.plosone.org 17 April 2011 | Volume 6 | Issue 4 | e19018rather than having been consistently wild type, although in this
study numbers are too small to be conclusive.
Viral fitness was measured using a recombinant assay in which a
patient-derived RT-PCR amplicon of HIV-1 gag-protease was
inserted into a gag-protease-deleted pNL4-3 plasmid. The advantage
of this approach is that it uses the full gag gene from the patient
sequence as well as the associated protease that encodes the enzyme
for cleavage of the Gag-Pol protein. The disadvantage of this assay
is that it is in a parallel rather than competitive format, and
therefore may lack sensitivity for small fitness differences. In
addition, the construct is a recombinant of a subtype B backbone
with a subtype C insert. Although this approach has been
published elsewhere [32], any data should be interpreted relative
to the control virus rather than as an absolute measure of viral
fitness. Choice of control is important. We used a subtype B wild-
type backbone (pNL4-3Dgag-protease) into which we recombined
the pNL4-3 gag-protease. This controlled for any change in fitness
due to the recombination step.
We found that VRC was significantly greater in patients with
low CD4 cell counts and there was a significant, although weak,
correlation with plasma viral load. These data, which are
consistent with a population-based study of HIV subtype B-
infected individuals [33], are amongst the first supporting a link
between viral fitness and plasma viral load, and show that this ex
vivo assay reflects viral replication in vivo. Analysing our data by
HLA Class I revealed that HLA Class I alleles that are associated
with clinical advantage (B*8101, B*57, B*5801) were associated
with impaired viral fitness, as had been inferred from previous
analyses of the reversion of transmitted escape mutations in HLA
mismatched hosts [22,23]. Interestingly, however, the increase in
viral fitness with lower CD4 cell counts did not appear to be
restricted to beneficial HLA alleles and was also present in a
selection of viruses from patients with ‘neutral/other’ alleles.
The HLA-amino acid association analysis showed that for HLA
B*8101 there was a decrease in mutations in the Gag TL9 epitope
at low CD4 cell counts, whereas for HLA B*57/B*5801 there was
persistence of the T242N escape mutation in TW10. The fitness
assays showed that the T186S mutation in TL9 was associated
with a fitness cost (P,0.0001) and it is therefore possible that in
patients with B*8101 and low CD4 counts, the decrease in
prevalence of the T186S mutation reflects reversion to a fitter
strain coincident with the weakening of T cell responses. For
B*57/B*5801 we saw a different pattern. Here, possession of HLA
B*57/B*5801 was associated with less fit viruses in conjunction
with the T242N mutation in the Gag TW10 epitope, but in
patients with low CD4 counts fitness was restored even though
T242N persisted. We therefore sought compensatory mutations to
explain this finding. For T242N there are four documented
compensatory mutations at Gag codons 219, 223, 228 and 248
[27]. For this analysis of subtype C HIV-1 we excluded codon 248,
as the 248A variant represents the subtype C consensus. When we
stratified patients with T242N according to CD4 strata we found a
significant (p=0.013) increase in numbers of compensatory
mutations at lower CD4 counts, consistent with the rise in VRC.
These data show that viral fitness increases with progression to
AIDS. Whether this is cause or effect is difficult to determine,
although the fact that we see evidence for both reversion and
compensatory mutations in the same cohort indicates that
progression may be a mixture of the two. What is clear is that
viral fitness is a significant component of progression to AIDS and,
as such, should be considered as a target for intervention, for
example through vaccines aimed at epitopes which escape with
Figure 6. Prevalence of compensatory mutations with the T242N mutation in the HLA-B57 and B*5801 restricted epitope, Gag
TW10. In the 100% stacked column, the y-axis shows the number of mutations accumulated at the three Gag protein amino acid sites (H219Q, I223V
and M228I) that compensate for the T242N mutation [27]. The x-axis depicts the categorical CD4 T cell count strata and the number of patients within
each strata (the ‘‘High CD4’’ group refers to patients with CD4 T cell counts .500 cells/ml, the ‘‘Intermediate CD4’’ group refers to patients with CD4 T
cell counts between 200 and 400 cells/ml, and the ‘‘Low CD4’’ group refers to patients with CD4 T cell counts ,100 cells/ml).
doi:10.1371/journal.pone.0019018.g006
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antiretroviral therapy can be extremely effective in regions such
as sub-Saharan Africa [41], however the costs and logistics of
provision are complex. Any intervention that could prevent new
infections or delay a requirement for therapy could have major
economic and health implications and therefore combining such a
vaccine with antiretroviral provision could be a productive
strategy.
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